亚洲 · 区域市场 · Korea Economic Daily
GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin
South Korea’s GC Biopharma Corp. and Hanmi Pharmaceutical Co. have licensed an experimental Fabry disease treatment to BioMarin Pharmaceutical Inc. in a ...
在 Korea Economic Daily 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.kedglobal.com)




